Ann-Lii Cheng, MD

Ann-Lii Cheng, MD, distinguished professor in the Department of Internal Medicine, director at Graduate Institute of Oncology, and director, Department of Medical Oncology, National Taiwan University College of Medicine, discusses where the of hepatocellular carcinoma (HCC) is headed.

For the past 10 years, Cheng says the responses have really hit the ceiling in terms of monotherapy. About 15% to 20% of patients with HCC respond to monotherapies, meaning 75% to 80% of patients do not have a response.

Videos

Ann-Lii Cheng, MD, discusses where the of hepatocellular carcinoma is headed.

Moving Forward From Monotherapy in HCC

Ann-Lii Cheng, MD, discusses a phase III trial of lenvatinib vs sorafenib in the first-line treatment of patients with unresectable hepatocellular carcinoma.

Ann-Lii Cheng, MD | Authors

Articles

Moving Forward From Monotherapy in HCC

Phase III Findings for Lenvatinib in HCC